Tenax Therapeutics (TENX) EBITDA Margin (2011 - 2015)

Tenax Therapeutics (TENX) has 4 years of EBITDA Margin data on file, last reported at 9874.97% in Q2 2015.

• For the quarter ending Q2 2015, EBITDA Margin changed N/A year-over-year to 9874.97%; the trailing twelve-month figure through Jun 2016 stood at 29548.27% (down 2863046.0% YoY), and the FY2015 full-year result was 33603.73%, changed N/A from the prior year.
• EBITDA Margin declined to 9874.97% in Q2 2015, from 938.82% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 6152.14% in Q2 2011 to a low of 9874.97% in Q2 2015.
• A 4-year average of 2298.55% and a median of 1110.67% in 2013 frame the typical range for EBITDA Margin.
• Peak annual rise in EBITDA Margin reached 913333 bps in 2012, while the deepest fall reached 810436 bps in 2012.
• Tracing TENX's EBITDA Margin over 4 years: stood at 3848.96% in 2011, then jumped by 97 bps to 134.04% in 2012, then tumbled by 600 bps to 938.82% in 2013, then sank by 952 bps to 9874.97% in 2015.
• Business Quant data shows TENX's EBITDA Margin at 9874.97% in Q2 2015, 938.82% in Q2 2013, and 715.64% in Q1 2013.